XMRV, prostate cancer and chronic fatigue syndrome

British Medical Bulletin

Volumn 98, Issue 1, 2011, Pages 61-74

  Kenyon, Julia C ^a   Lever, Andrew M L ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

chronic fatigue syndrome; prostate cancer; XMRV

Indexed keywords

ANTIRETROVIRUS AGENT; DOUBLE STRANDED RNA; INTERFERON; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RIBONUCLEASE L; VIRUS RNA;

AMINO ACID SUBSTITUTION; ANTIVIRAL THERAPY; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHRONIC FATIGUE SYNDROME; COHORT ANALYSIS; DISEASE ASSOCIATION; DNA MICROARRAY; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE RESULT; FAMILY HISTORY; FLUORESCENCE IN SITU HYBRIDIZATION; GAMMARETROVIRUS INFECTION; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; LABORATORY TEST; NUCLEIC ACID ANALYSIS; PHYLOGENETIC TREE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRUS IDENTIFICATION; VIRUS REPLICATION; XENOTROPIC MULV RELATED VIRUS; XENOTROPIC MULV RELATED VIRUS INFECTION;

CELL TRANSFORMATION, NEOPLASTIC; FATIGUE SYNDROME, CHRONIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RETROVIRIDAE INFECTIONS; XENOTROPIC MURINE LEUKEMIA VIRUS-RELATED VIRUS;

EID: 79958822345     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldr010     Document Type: Article

References (46)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37(Suppl. 8):S4-66.
2. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Sakr WA, Grignon DJ, Haas GP et al. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996;30:138-44. (Pubitemid 26285528)
4. Bratt O. Hereditary prostate cancer: clinical aspects. J Urol 2002;168:906-13.
5. De Marzo AM, Platz EA, Sutcliffe S et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69. (Pubitemid 46486616)
6. Urisman A, Molinaro RJ, Fischer N et al. Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2006;2:e25.
7. Casey G, Neville PJ, Plummer SJ et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002;32:581-3. (Pubitemid 35435169)
8. Eckhart W. Viruses and human cancer. Sci Prog 1998;81(Pt 4):315-28.
9. Arnold RS, Makarova NV, Osunkoya AO et al. XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH. Urology 2010;75:755-61.
10. Schlaberg R, Choe DJ, Brown KR et al. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci USA 2009;106:16351-6.
11. Danielson BP, Ayala GE, Kimata JT. Detection of xenotropic murine leukemia virus-related virus in normal and tumor tissue of patients from the southern United States with prostate cancer is dependent on specific polymerase chain reaction conditions. J Infect Dis 2010;202:1470-7.
12. Metzger MJ, Holguin CJ, Mendoza R et al. The prostate cancer-associated human retrovirus XMRV lacks direct transforming activity but can induce low rates of transformation in cultured cells. J Virol 2010;84:1874-80.
13. Kim S, Kim N, Dong B et al. Integration site preference of xenotropic murine leukemia virusrelated virus, a new human retrovirus associated with prostate cancer. J Virol 2008;82:9964-77.
14. Rodriguez JJ, Goff SP. Xenotropic murine leukemia virus-related virus establishes an efficient spreading infection and exhibits enhanced transcriptional activity in prostate carcinoma cells. J Virol 2010;84:2556-62.
15. Dong B, Silverman RH. Androgen stimulates transcription and replication of xenotropic murine leukemia virus-related virus. J Virol 2010;84:1648-51.
16. Knouf EC, Metzger MJ, Mitchell PS et al. Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells. J Virol 2009;83:7353-6.
17. Hohn O, Krause H, Barbarotto P et al. Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients. Retrovirology 2009;6:92.
18. Fischer N, Hellwinkel O, Schulz C et al. Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol 2008;43:277-83.
19. Verhaegh GW, de Jong AS, Smit FP et al. Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in Dutch prostate cancer patients. Prostate 2010;71:415-20.
20. Aloia AL, Sfanos KS, Isaacs WB et al. XMRV: a new virus in prostate cancer? Cancer Res 2010;70:10028-33.
21. Smith RA. Contamination of clinical specimens with MLV-encoding nucleic acids: implications for XMRV and other candidate human retroviruses. Retrovirology 2010;7:112.
22. Sato E, Furuta RA, Miyazawa T. An endogenous murine leukemia viral genome contaminant in a commercial RT-PCR Kit is amplified using standard primers for XMRV. Retrovirology 2010;7:110.
23. Robinson MJ, Erlwein OW, Kaye S et al. Mouse DNA contamination in human tissue tested for XMRV. Retrovirology 2010;7:108.
24. Oakes B, Tai AK, Cingoz O et al. Contamination of human DNA samples with mouse DNA can lead to false detection of XMRV-like sequences. Retrovirology 2010;7:109.
25. Lombardi VC, Ruscetti FW, Das Gupta J et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009;326:585-9.
26. Dinos S, Khoshaba B, Ashby D et al. A systematic review of chronic fatigue, its syndromes and ethnicity: prevalence, severity, co-morbidity and coping. Int J Epidemiol 2009;38:1554-70.
27. Erlwein O, Kaye S, McClure MO et al. Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS One 2010;5:e8519.
28. Groom HC, Boucherit VC, Makinson K et al. Absence of xenotropic murine leukaemia virusrelated virus in UK patients with chronic fatigue syndrome. Retrovirology 2010;7:10.
29. van Kuppeveld FJ, de Jong AS, Lanke KH et al. Prevalence of xenotropic murine leukaemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: retrospective analysis of samples from an established cohort. BMJ 2010;340:c1018.
30. Hong P, Li J, Li Y. Failure to detect Xenotropic murine leukaemia virus-related virus in Chinese patients with chronic fatigue syndrome. Virol J 2010;7:224.
31. Henrich TJ, Li JZ, Felsenstein D et al. Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions. J Infect Dis 2010;202:1478-81.
32. Switzer WM, Jia H, Hohn O et al. Absence of evidence of xenotropic murine leukemia virusrelated virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology 2010;7:57.
33. Lo SC, Pripuzova N, Li B et al. Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad Sci USA 2010;107:15874-9.
34. Hue S, Gray ER, Gall A et al. Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology 2010;7:111.
35. Garson JA, Kellam P, Towers GJ. Analysis of XMRV integration sites from human prostate cancer tissues suggests PCR contamination rather than genuine human infection. Retrovirology 2011;8:13.
36. Hohn O, Strohschein K, Brandt AU et al. No evidence for XMRV in German CFS and MS patients with fatigue despite the ability of the virus to infect human blood cells in vitro. PLoS One 2010;5:e15632.
37. Chaipan C, Dilley KA, Paprotka T et al. Severe restriction of xenotropic murine leukemia virus-related virus replication and spread in cultured human peripheral blood mononuclear cells. J Virol 2011. [Epub ahead of print.]
38. Tang S, Zhao J, Viswanath R et al. Absence of detectable xenotropic murine leukemia virusrelated virus in plasma or peripheral blood mononuclear cells of human immunodeficiency virus Type 1-infected blood donors or individuals in Africa. Transfusion 2010;51:463-8.
39. McCormick AL, Brown RH Jr, Cudkowicz ME et al. Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurology 2008;70:278-83. (Pubitemid 351156807)
40. Barnes E, Flanagan P, Brown A et al. Failure to detect xenotropic murine leukemia virusrelated virus in blood of individuals at high risk of blood-borne viral infections. J Infect Dis 2010;202:1482-5.
41. Jeziorski E, Foulongne V, Ludwig C et al. No evidence for XMRV association in pediatric idiopathic diseases in France. Retrovirology 2010;7:63.
42. Fischer N, Schulz C, Stieler K et al. Xenotropic murine leukemia virus-related gammaretrovirus in respiratory tract. Emerg Infect Dis 2010;16:1000-2.
43. Paprotka T, Venkatachari NJ, Chaipan C et al. Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs. J Virol 2010;84:5719-29.
44. Groom HC, Yap MW, Galao RP et al. Susceptibility of xenotropic murine leukemia virusrelated virus (XMRV) to retroviral restriction factors. Proc Natl Acad Sci USA 2010;107:5166-71.
45. Sakuma R, Sakuma T, Ohmine S et al. Xenotropic murine leukemia virus-related virus is susceptible to AZT. Virology 2010;397:1-6.
46. Singh IR, Gorzynski JE, Drobysheva D et al. Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. PLoS One 2010;5:e9948.